Increasing Biopharmaceutical Production is set to Boost Demand for Mycoplasma detection Devices to Ensure Product Safety
Mycoplasma detection is gaining significant traction in the biopharmaceuticals industry. Biopharmaceuticals represent around one-fourth share of total pharmaceutical industry revenue generation which is growing year on year by a substantial rate.
The superior efficacy of biopharmaceuticals in treating chronic diseases is making them the choice of treatment which in turn is increasing biopharmaceutical production. Mycoplasma is the most common contaminant in the biopharmaceuticals industry, therefore mycoplasma detection devices are gaining significant adoption to ensure biopharmaceuticals product safety.
With constantly evolving contamination detection techniques and the growing adoption of biopharmaceuticals in healthcare, this is expected to create several opportunities for mycoplasma detection market growth.
Higher Operational Efficiency with PCR based Mycoplasma Detection Technique Compare to Traditional Detection
The PCR based mycoplasma detection technique is alternative to costly, time-consuming culture-based tests which often done externally by contract labs and it can take up to 28 days. Mycoplasma detection is used at different stages of manufacturing, to eliminate the faulty batch and not the entire set of production batches.
The traditional detection of mycoplasma contamination using culture-based test often requires close to 4 weeks whereas mycoplasma testing using advanced methods such as kits and systems often provides instant results with a minimum margin of error.
For example, MycoSEQ assay (By Thermo Fisher Scientific) can identify more than 90 mycoplasma species in under five hours, with well-documented specificity and sensitivity.
Introduction of Cost-Effective Detection Kits is Key Strategy Adopted by Regional Manufacturers
Technological advances related to sample collection, testing and efforts by manufacturers to create easy to use test kits are expected to create high demand for mycoplasma detection kits and systems.
Manufacturers in various regions are focusing on developing cost-effective testing kits and systems to enhance their product adoption among the contract manufacturers and contract research organizations Adoption of mycoplasma detection is largely concentrated in developed regions such as North America, Europe and some parts of Asia-Pacific.
It however has limited penetration in untapped biopharmaceutical markets such as Latin America and Middle East & Africa. Hence, there is vast scope for manufacturing of cost-effective products and improving availability.
Academia to Emerge as Primary Research Organization
Academic research institutes have focused on advanced basic research, including applied research when the government or industrial organizations prefer cost-effective ways to pursue development programs.
A majority of basic research continues to be carried out at academia as companies focus on bringing products to the market to generate profits. According to the National Science Foundation’s 2012 report, 56% of basic research conducted in the US is carried out in academia, whereas 61% of all applied research and 87% of development happens in the industry.
A strong scientific and technological expertise available with academic research laboratories and research programs by them will create strong demand for the mycoplasma detection devices and kits.
Avail customized purchase options for your needs
COVID-19 Market Insights:
The recent COVID-19 outbreak has brought the world to a standstill. Every day, innumerable cases of infections are reported, with scores of people dying from it. As the incidence of the disease rises, companies are leaving no stone unturned in ensuring the safety of their employees as well as investing available resources into finding a cure for this life-threatening disease.
Recent research into the cures for the coronavirus suggests that quantitative real-time polymerase chain reaction (q RT-PCR) test is an important approach towards mitigating the spread of the disease.
The PCR tests are equally useful in detecting the presence of mycoplasma in cell cultures. This common application of PCR techniques in both COVID-19 eradication as well as mycoplasma detection is anticipated to provide greater scope for its research and development in the future.
On the back of this, the mycoplasma detection market is set for expansion. For example, Thermo Fisher Scientific has invested a significant amount of its resources in PCR techniques, particularly qPCR workflow research products. Likewise, Bio-Rad Laboratories, another leading player in the PCRs market, markets the Reliance One-Step RT-qPCR Supermix, the CFX Real-Time PCR Detection Systems and CFX96 Dx Systems.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.